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Abstract
Background: Psychosis can be associated with acute recreational drug and novel psychoactive substance (NPS)
toxicity. However, there is limited data available on how common this is and which drugs are most frequently
implicated. We describe a European case series of psychosis associated with acute recreational drug toxicity, and
estimate the frequency of psychosis for different recreational drugs.
Methods: The European Drug Emergencies Network (Euro-DEN) collects data on presentations to Emergency
Departments (EDs) with acute recreational drug and NPS toxicity at 16 centres in ten countries. Euro-DEN
data from October 2013 through September 2014 was retrospectively searched, and cases with psychosis
were included. The proportion of cases with psychosis per drug was calculated in the searched Euro-DEN
dataset.
Results: Psychosis was present in 348 (6.3 %) of 5529 cases. The median (interquartile range) age was 29
(24-38) years, 276 (79.3 %) were male and 114 (32.8 %) were admitted to psychiatric ward. The drugs most
commonly reported were cannabis in 90 (25.9 %) cases, amphetamine in 87 (25.0 %) and cocaine in 56
(16.1 %). More than one drug was taken in 189 (54.3 %) cases. Psychosis was frequent in those ED
presentations involving tryptamines (4/7; 57.1 %), methylenedioxypyrovalerone (MDPV) (6/22; 27.3 %),
methylphenidate (6/26; 23.1 %), lysergic acid diethylamide (LSD) (18/86; 20.9 %), psilocybe mushrooms
(3/16; 18.8 %), synthetic cannabinoid receptor agonists (4/26; 15.4 %) and amphetamine (87/593; 14.7 %),
but less common in those involving mephedrone (14/245; 5.7 %), methylenedioxymethamphetamine (MDMA)
(20/461; 4.3 %) and methedrone (3/92; 3.3 %). Amphetamine was the most frequent drug associated with psychosis
when only one agent was reported, with psychosis occurring in 32.4 % of these presentations.
Conclusion: The frequency of psychosis in acute recreational drug toxicity varies considerably between drugs, but is a
major problem in amphetamine poisoning. In rapidly changing drug markets and patterns of use, the Euro-DEN
sentinel network contributes to measuring the scale of drug-related harms in Europe beyond other more established
indicators.
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Background
Acute psychosis is a serious medical condition associated
with significant morbidity [1]. Use of classic sympatho-
mimetic drugs like amphetamine, methamphetamine
and cocaine can induce acute psychosis [2–4]. Whilst
the prevalence of psychosis in the community has been
estimated at about 0.5 % [5, 6], the prevalence of drug
induced psychosis among regular drug users has been
reported to be in the range of 8-46 % for amphetamine
[2] and 7-86 % for cocaine [3]. The wide ranges are
probably due to variations in methods of data collection
and the populations studied [2, 3]. Recent decades have
seen an increased potency of cannabis preparations [7–
9], carrying an increased risk of psychosis [10]. Though
most drug induced psychoses resolve within a few days,
as many as 8-27 % have been reported to persist for
more than one month [11–13].
Over the last decade there has been an increase in the
availability and use of a multitude of novel psychoactive
substances (NPS), with 101 new substances reported to
the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) in 2014 [8]. These NPS encom-
pass a variety of drug classes, including the cathinones,
phenethylamines, tryptamines, piperazines and synthetic
cannabinoid receptor agonists (SCRA) [14–17]. There
have been numerous reports of acute NPS toxicity asso-
ciated with psychosis, involving several different drugs,
among them methylenedioxypyrovalerone (MDPV),
mephedrone, alpha-methyltryptamine (AMT), 6-(2-ami-
nopropyl)benzofuran (6-APB), diphenylprolinol (D2PM),
and SCRAs [17–28]. However, there is limited data avail-
able on how common psychosis is in patients presenting
with acute recreational drug or NPS toxicity and which
drugs are most frequently implicated.
The European Drug Emergencies Network (Euro-
DEN) is a European Commission funded project which
collected data on presentations to Emergency Depart-
ments (EDs) with acute recreational drug and NPS tox-
icity in 16 sentinel centres in ten European countries
[29]. This has been continued as the Euro-DEN Plus
network following completion of the initial project, with
the aim of increasing the number of centres and cover-
age across Europe.
Methods
The aim of this study was to describe the cases of psych-
osis associated with acute recreational drug and NPS
toxicity reported in the first year of the Euro-DEN pro-
ject and to estimate the psychosis rate in acute toxicity
presentations with different recreational drugs and NPS.
We have previously described the Euro-DEN method-
ology in detail [29]. The participating centres were
mainly hospital emergency departments, some were spe-
cialist toxicology units, and one was a primary care
emergency outpatient clinic. For the remainder of this
article we will use the term recreational drugs to encom-
pass both classical recreational drugs and NPS.
Inclusion
Patients presenting to a participating Euro-DEN centre
with symptoms and/or signs consistent with acute recre-
ational drug toxicity and/or directly related to recre-
ational drug use were included in Euro-DEN;
presentations with isolated ethanol intoxication were ex-
cluded. Recreational drugs were defined as any psycho-
active compound taken for recreational rather than for
medical or work purposes or deliberate self-harm (this
included classical recreational drugs, NPS and prescrip-
tion medicines); the drug(s) involved in the presentation
were based on the patient’s self report and/or the clinical
assessment of the treating physician. For each included
case we collected a minimum data set of pre-defined
demographic, clinical and outcome variables from infor-
mation in the patients’ medical records. For this study,
Euro-DEN data from October 2013 through September
2014 were retrospectively searched, and all presentations
with psychosis as a clinical feature were included.
Psychosis was one of the pre-defined clinical features
collected in the minimum data set. Psychosis was de-
fined as any episode of delusions, transient or persistent,
accompanied by confusion, hallucinations and lack of
insight, based on the assessment of the treating clinician
as documented in the patient’s notes.
Data extraction
The data extracted for this study were: age and gender,
drugs taken, clinical observations at presentation
(temperature, heart rate, blood pressure, respiratory rate,
conscious level, blood glucose), clinical features (psych-
osis, hallucinations, agitation, anxiety, hyperthermia),
treatment and outcome (disposition from the ED, length
of hospital stay and death in hospital).
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Outcome measures
We calculated the proportion of presentations with
psychosis for each drug amongst all presentations in the
Euro-DEN dataset where the drug was reported, whether
as a sole drug or in combination with others. We also
calculated the odds ratio (OR) for presenting with psych-
osis for each drug.
Ethics
The study was done in accordance with the Helsinki
declaration. Each centre obtained appropriate ethical ap-
proval to collect the data from their institution. Written
consent from the patients was not necessary, as no data
other than that collected as part of the routine clinical
examination was being used for the project.
Statistics
Pearson’s chi-square test or Fisher’s exact test (for expected
cell values five or less) were used to compare frequencies.
T-test or Mann-Whitney U-test were used in comparisons
of continuous variables. Logistic regression analyses were
used to estimate the association between psychosis and dif-
ferent recreational drugs. For each drug the patients pre-
senting without psychosis were defined as the reference
group (OR = 1). In the multivariate analyses the odds ratios
for psychosis being a clinical feature associated with a drug
were adjusted for other drugs reported (Table 3). Analyses
were done in IBM SPSS version 21 (IBM Corp.) and in an
online calculator from EpiTools epidemiological calcula-
tors (http://epitools.ausvet.com.au) [30].
Results
Over the 12 month period there were 5529 cases with
acute recreational drug toxicity reported to the Euro-
DEN project from the participating centres, and psych-
osis was recorded as a clinical feature in 348 (6.3 %).
Table 1 lists the number of presentations with psychosis
at each of the participating centres; the proportion of
presentations with psychosis varied from 3.0 to 16.3 %.
Amongst the patients presenting with psychosis, the
median (interquartile range (IQR)) age was 29 (24-38)
years, and 276 (79.3 %) were male (Table 2). In addition
to psychosis, 63.2 % had agitation, and 43.7 % had hallu-
cinations (Table 2). The drugs most commonly reported
in the presentations with psychosis were cannabis in 90
(25.9 % of the psychosis presentations), amphetamine in
87 (25.0 %) and cocaine in 56 (16.1 %). More than one
drug was taken in 189 (54.3 %) of the presentations with
psychosis, including 105 (30.2 %) cases in which ethanol
was co-ingested.
The strongest associations with psychosis were found
for tryptamines (psychosis in 57.1 % of presentations; ad-
justed OR 12.4), MDPV (27.3 %; adjusted OR 6.5), me-
thylphenidate (23.1 %; adjusted OR 3.9), lysergic acid
diethylamide (LSD) (20.9 %; adjusted OR 3.1), amphet-
amine (14.7 %; adjusted OR 3.0), and methamphetamine
(11.3 %; adjusted OR 2.3) (Table 3).
In the 159 single agent cases, the largest proportions
of presentations with psychosis were found for trypt-
amines (2/2; 100 %), MDPV (2/2;100 %), methylphenid-
ate (2/5; 40.0 %), amphetamine (44/136; 32.4 %), and
LSD (7/27; 25.9 %) (Table 3). For benzodiazepines the
proportion of presentations with psychosis was small
(3.4 %), and nearly all (94.1 %) benzodiazepine cases
with psychosis were in combination with other drugs.
Treatment was required in 192 (55.2 %) of the presenta-
tions with psychosis, including sedation in 154 (44.3 %).
The most common sedatives/antipsychotics given were
benzodiazepines in 127 (36.5 %) cases, olanzapine in 27
(7.8 %), haloperidol in 26 (7.5 %) and propofol in 14 (4.0 %).
The median length of stay in hospital was 5.1 hours (IQR
2.3-13.6). In 132 (37.9 %) cases the patient was medically
discharged from the ED, a significantly lower proportion
than the 58.2 % among those without psychosis (p < 0.001)
(Table 2). In 114 (32.8 %) cases the patient was admitted to
a psychiatric ward, compared to 3.3 % among those without
psychosis (p < 0.001). There was no difference in the pro-
portions admitted to critical care.
Table 1 Presentations with psychosis associated with acute
recreational drug toxicity, per participating Euro-DEN centre
Centre, Country Total
presentations
n
Presentations with
psychosis
n (%)
Barcelona, Spain 199 22 (11.1)
Basel, Switzerland 216 12 (5.6)
Copenhagen,
Denmark
183 6 (3.3)
Drogheda, Ireland 36 4 (11.1)
Dublin, Ireland 526 19 (3.6)
Gdansk, Poland 144 17 (11.8)
London KCH, UK 422 13 (3.1)
London STH, UK 956 29 (3.0)
Mallorca, Spain 181 12 (6.6)
Munich, Germany 214 22 (10.3)
Oslo OAEOC, Norway 1478 113 (7.6)
Oslo OUH, Norway 199 9 (4.5)
Paris, France 454 42 (9.3)
Pärnu, Estonia 15 1 (6.7)
Tallinn, Estonia 104 17 (16.3)
York, UK 202 10 (5.0)
Total 5529 348 (6.3)
KCH: King’s College Hospital NHS Foundation Trust
OAEOC: Oslo Accident and Emergency Outpatient Clinic
OUH: Oslo University Hospital
STH: St Thomas’ Hospital (Guy’s and St Thomas’ NHS Foundation Trust)
UK: United Kingdom of Great Britain and Northern Ireland
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Discussion
Psychosis was a clinical feature in 6.3 % of this European
case series of 5529 presentations to an ED with acute
recreational drug toxicity. The association with psychosis
varied considerably between drugs. Not surprisingly, the
associations were strongest for hallucinogens and some
central stimulants. Overall, cannabis, amphetamine and
cocaine were the drugs most commonly involved in pre-
sentations with psychosis. Amphetamine was the drug
most frequently involved in single agent presentations,
with 32.4 % single agent amphetamine cases presenting
with psychosis. Amongst the NPS, psychosis was rare in
presentations involving mephedrone and methedrone,
but occurred more frequently with tryptamines, MDPV,
methylphenidate and the SCRAs.
Among the patients presenting with recreational drug
toxicity and psychosis, 63.2 % were agitated and/or ag-
gressive (compared to 24.1 % of those without psych-
osis), 43.7 % had hallucinations (compared to 4.5 %), and
32.8 % were admitted to a psychiatric ward (compared
to 3.3 %), indicating that this is a group of patients with
substantial resource implications. Furthermore, acute
Table 2 Presentations with psychosis – demographics, clinical data and disposition from the ED
Presentations with psychosis Presentations without psychosis
n (%) median (IQR) mean (SD) n (%) median (IQR) mean (SD) p-value
Age
Total 29 years (24-38) 31 years (24-39) 0.077b
Males 276 (79.3)a 29 years (24-38) 3892 (75.1)a 32 years (25-39) 0.041b
Females 72 (20.7)a 26.5 years (22-39) 1289 (24.9)a 28 years (22-37) 0.675b
Observations at presentation
Respiratory rate 18 /min (5) 16 /min (5) <0.001
Heart rate 100 /min (22) 91 /min (24) < 0.001
Systolic blood pressure 131 mmHg (20) 125 mmHg (21) < 0.001
Diastolic blood pressure 80 mmHg (16) 77 mmHg (16) 0.004
Temperature 36.7 °C (0.8) 36.3 °C (0.9) < 0.001
Blood glucose 5.7 mmol/L (5.1-6.9) 5.6 mmol/L (4.9-6.7) 0.079
Conscious level
Alert (GCS 15) 203 (58.3) 2564 (49.5) 0.002
Drowsy (GCS 8-14) 122 (35.1) 2013 (38.9) 0.002
Comatose (GCS≤ 7) 9 (2.6) 448 (8.6) < 0.001
Not recorded 14 (4.0) 156 (3.0) 0.369
Clinical features
Hallucinations 152 (43.7) 232 (4.5) < 0.001
Agitation/aggression 220 (63.2) 1247 (24.1) < 0.001
Anxiety 129 (37.1) 911 (17.6) < 0.001
Hyperthermia 7 (2.0) 67 (1.3) 0.375
Disposition from ED
Medically discharged 132 (37.9) 3016 (58.2) < 0.001
Self discharge 50 (14.4) 906 (17.5) 0.157
Admitted critical care 14 (4.0) 318 (6.1) 0.140
Admitted psychiatric ward 114 (32.8) 170 (3.3) < 0.001
Admitted other 38 (10.9) 739 (14.3) 0.097
Death - 16 (0.3) 0.601
Unknown - 16 (0.3) 0.601
Length of stay in hospital 5.1 hours (2.3-13.6) 4.6 hours (2.5-9.7) 0.176
Total 348 (100) 5181 (100)
aNo significant difference in gender proportions between presentations with and without psychosis (p = 0.091)
bp-value for comparison of age
ED: emergency department; GCS: Glasgow Coma Scale; IQR: interquartile range; SD: standard deviation
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psychosis induced by substance use is, until it has re-
solved, difficult to distinguish clinically from schizo-
phrenic psychosis [31, 32]. Some authors have questioned
whether they are separate entities at all [2, 33–35]. Longer
duration of untreated psychosis is associated with poorer
outcome, though a causal relationship has not been
Table 3 Drugs associated with psychosis – logistic regression analysis
All presentations where
the drug was reported
Crude Adjusted Presentations where the drug
was the single agent reported
Drug Total
n (%)
With psychosis
n (%)
Odds ratio 95 % CI p-value Odds ratio 95 % CI p-value Total
n (%)
With psychosis
n (%)
Tryptamines 7 (0.1) 4 (57.1) 20.1 4.5 – 90.0 < 0.001 12.4 2.3 – 65.2 0.003 2 (0.1) 2 (100)
MDPV 22 (0.4) 6 (27.3) 5.7 2.2 – 14.6 < 0.001 6.5 2.2 – 19.2 0.001 2 (0.1) 2 (100)
Methylphenidate 26 (0.5) 6 (23.1) 4.5 1.8 – 11.3 0.001 3.9 1.5 – 10.2 0.006 5 (0.2) 2 (40.0)
LSD 86 (1.6) 18 (20.9) 4.1 2.4 – 7.0 < 0.001 3.1 1.8 – 5.5 < 0.001 27 (1.3) 7 (25.9)
Amphetamine 593 (10.7) 87 (14.7) 3.1 2.4 – 4.0 < 0.001 3.0 2.3 – 4.0 < 0.001 136 (6.7) 44 (32.4)
Methamphetamine 186 (3.4) 21 (11.3) 2.0 1.2 – 3.1 0.005 2.3 1.4 – 3.8 0.001 44 (2.2) 8 (18.2)
Psilocybe mushroomsa 16 (0.3) 3 (18.8) 3.5 0.98 – 12.2 0.054 2.2 0.60 – 8.0 0.24 6 (0.3) 1 (16.7)
SCRA 26 (0.5) 4 (15.4) 2.7 0.93 – 8.0 0.066 1.8 0.61 – 5.4 0.29 17 (0.8) 3 (17.6)
Cannabis 904 (16.4) 90 (10.0) 1.9 1.5 – 2.4 < 0.001 1.5 1.2 – 2.0 0.002 216 (10.6) 31 (14.4)
Z-drugs 106 (1.9) 8 (7.5) 1.2 0.59 – 2.5 0.59 1.4 0.68 – 3.1 0.34 16 (0.8) -
Fentanyl 47 (0.9) 4 (8.5) 1.4 0.50 – 3.9 0.53 1.3 0.44 – 3.9 0.64 10 (0.5) 2 (20.0)
Tramadol 34 (0.6) 3 (8.8) 1.4 0.44 – 4.7 0.55 1.3 0.39 – 4.7 0.64 5 (0.2) 1 (20.0)
Crack 136 (2.5) 6 (4.4) 0.68 0.30 – 1.6 0.36 1.1 0.45 – 2.5 0.89 24 (1.2) 3 (12.5)
Cocaine 957 (17.3) 56 (5.9) 0.91 0.68 – 1.2 0.54 0.93 0.68 – 1.3 0.65 164 (8.1) 11 (6.7)
Pregabalin 79 (1.4) 4 (5.1) 0.79 0.29 – 2.2 0.65 0.92 0.31 – 2.8 0.88 3 (0.1) -
Mephedrone 245 (4.4) 14 (5.7) 0.90 0.52 – 1.6 0.70 0.90 0.50 – 1.6 0.72 72 (3.5) 4 (5.6)
Buprenorphine 89 (1.6) 6 (6.7) 1.1 0.47 – 2.5 0.86 0.90 0.36 – 2.2 0.82 16 (0.8) 1 (6.3)
Ketamine 128 (2.3) 5 (3.9) 0.60 0.24 – 1.5 0.27 0.59 0.23 – 1.5 0.26 12 (0.6) -
MDMA 461 (8.3) 20 (4.3) 0.66 0.41 – 1.0 0.073 0.58 0.36 – 0.95 0.030 59 (2.9) -
Benzodiazepines 1011 (18.3) 34 (3.4) 0.47 0.33 – 0.67 < 0.001 0.53 0.36 – 0.78 0.001 79 (3.9) 2 (2.5)
Methedrone 92 (1.7) 3 (3.3) 0.50 0.16 – 1.6 0.24 0.49 0.15 – 1.6 0.24 21 (1.0) 1 (4.8)
GHB/GBL 710 (12.8) 25 (3.5) 0.51 0.34 – 0.77 0.001 0.38 0.25 – 0.59 < 0.001 215 (10.6) 4 (1.9)
Methadone 248 (4.5) 6 (2.4) 0.36 0.16 – 0.81 0.014 0.34 0.14 – 0.80 0.014 38 (1.9) 1 (2.6)
Heroin 1344 (24.3) 21 (1.6) 0.19 0.12 – 0.29 < 0.001 0.18 0.11 – 0.28 < 0.001 564 (27.8) 8 (1.4)
Other cathinones 20 (0.4) 4 (20.0) 3.8 1.2 – 11.3 0.019 3.0 0.97 – 9.4 0.057 10 (0.5) 1 (10.0)
Other amphetamine
derivatives
27 (0.5) 4 (14.8) 2.6 0.90 – 7.6 0.078 1.8 0.57 – 5.5 0.33 4 (0.2) 2 (50.0)
Other stimulants 36 (0.7) 5 (13.9) 2.4 0.94 – 6.4 0.068 2.0 0.75 – 5.3 0.17 8 (0.4) 3 (37.5)
Other hallucinogens 55 (1.0) 8 (14.5) 2.6 1.2 – 5.5 0.015 2.3 1.0 – 5.1 0.040 20 (1.0) 3 (15.0)
Ethanolb 2145 (38.8) 105 (4.9) 0.66 0.53 – 0.84 < 0.001 0.54 0.42 – 0.69 < 0.001 - -
Other opioids 204 (3.7) 5 (2.5) 0.36 0.15 – 0.89 0.031 0.30 0.12 – 0.75 0.010 51 (2.5) -
Total 5529 (100)c 348 (6.3) 2030 (100) 159 (7.8)
Adjusted odds ratios with p < 0.05 are given in bold types
CI: confidence interval
GBL: gamma-butyrolactone
GHB: gamma-hydroxybutyrate
LSD: lysergic acid diethylamide
MDMA: methylenedioxymethamphetamine
MDPV: methylenedioxypyrovalerone
NPS: novel psychoactive substances
SCRA: Synthetic cannabinoid receptor agonists
aIncludes three presentations reporting psilocybin
bEthanol only included as co-ingestion
cPercentages do not add up to 100 as in several cases more than one drug was reported
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established [36]. However, there is evidence suggesting
that early intervention, reducing the duration of untreated
psychosis, could be helpful [37–39].
Cannabis, amphetamine and cocaine were the drugs
most commonly involved in presentations with psychosis
in our study. This is to be expected as they are com-
monly used in Europe [8] and carry the risk of inducing
acute psychosis [2, 3, 40]. We found amphetamine more
frequently associated with psychosis than cannabis and
cocaine, both as a single agent and in the logistic regres-
sion analysis, confirming that psychosis is a major fea-
ture of acute amphetamine toxicity. Cannabis, but not
cocaine, was significantly associated with psychosis in
the logistic regression analysis.
Among the NPS, tryptamines, MDPV and SCRAs were
the drugs most frequently involved in presentations with
psychosis. In our study, 57.1 % of patients with trypta-
mine poisoning presented with psychosis, a larger pro-
portion than the 23.6 % reported among 55 enquiries
concerning AMT in a poison centre case series in the
UK [27]. This substantiates previous reports noting
psychosis as a prominent clinical feature of acute trypta-
mine toxicity [41]. In a study of 23 patients with acute
MDPV toxicity seen by medical toxicologists in the US,
psychosis was reported in 8.7 % [28]. This is less than
the 27.3 % in our study, and our findings are more in
keeping with a US poison centre study of 236 cases of
MDPV toxicity, where 36 % had paranoia, 34 % confu-
sion and 40 % hallucinations [18]. In our study, 15.4 %
of those presenting with acute SCRA toxicity had psych-
osis – this is comparable to the 9-11 % reporting halluci-
nations and delusion to US poison centres in two case
series of 1353 and 418 acute SCRA exposures [23, 24].
However, a German case series of 29 ED presentations
with laboratory confirmed acute SCRA toxicity reported
only one case of acute psychosis though 38 % of the pa-
tients had hallucinations or changes of perception [42].
For mephedrone, 5.7 % of patients in our study pre-
sented with psychosis, slightly less than the 8 % reported
among 488 enquiries to UK poison centres [27] and the
9 % with paranoia and hallucinations among 57 presen-
tations to the ED in a Scottish case series [43]. No
psychotic features were reported among seven cases with
laboratory confirmed mephedrone toxicity in a London
ED [44].
Psychosis has previously been reported as a feature of
acute methylphenidate toxicity as well as a potential side
effect of methylphenidate treatment [45]. In our study,
23.1 % of presentations involving methylphenidate had
psychosis.
Tramadol and fentanyl differed from the other opioids,
with a larger proportion of presentations with psychosis.
Though only seven cases with psychosis were seen in-
volving these drugs, two were single agent cases with
fentanyl and one with tramadol. We have only found
one previous report of psychosis as a clinical feature of
tramadol toxicity [46], and none involving fentanyl.
In addition to the risk of inducing acute psychosis,
regular use of several recreational drugs, especially am-
phetamine, methamphetamine and cannabis, has been
shown to be associated with later development of
chronic psychosis or schizophrenia [2, 11, 34, 47]. Japa-
nese studies have reported schizophrenia-like psychosis
in methamphetamine users persisting for months to
years after discontinuation of methamphetamine use [11,
33]. A large cohort study in California found an in-
creased risk of later being diagnosed with schizophrenia
in previously non-psychotic hospitalised users of meth-
amphetamine or cannabis [34]. A meta-analysis of seven
studies found cannabis use to be an independent risk
factor for later development of chronic psychosis [47].
The risk was higher the more cannabis was used, and
the earlier in life the start of the exposure [47]. It also
seems that patients with previous substance use associ-
ated psychosis are at greater risk of subsequent psych-
otic episodes [2, 33].
Limitations
Data on previous psychiatric diagnoses were not col-
lected. Therefore, we are not able to determine whether
the psychosis seen at the time of the acute recreational
drug toxicity presentation was an acute psychosis, the
patient’s regular psychotic state or an exacerbation of a
chronic psychosis. Furthermore, we did not collect infor-
mation on the frequency or duration of drug use. It is
possible that large proportions of presentations with
psychosis reflect drugs of choice for patients with
chronic psychosis [48]. We do not have any follow-up
data for the patients in our study. However, the short
length of stay and high proportion of patients medically
discharged from the ED suggests that in a substantial
proportion the psychosis was of limited duration.
The diagnosis of psychosis was made by the treating
ED clinician, and not necessarily by a psychiatrist.
Consequently, there is a potential for misdiagnosis; al-
though this represents routine clinical practice and
assessment/management of patients in European EDs
with acute recreational drug toxicity. There may also
be inconsistencies in the diagnosis of psychosis across
countries. This may possibly contribute to the vari-
ation of psychosis rates between centres seen in our
material. The diagnosis of psychosis was mainly based
on the assessment of the clinician treating the patient.
Therefore, some inter-rater variability must be ex-
pected. On the other hand, our results are based on
decisions made in real clinical situations, strengthen-
ing their generalizability.
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Drug(s) involved in the presentations were based on
patient self-report. Patients may not report all drugs
ingested, and may not know the actual psychoactive in-
gredient in the substance(s) taken. There is the potential
that this will lead to some misclassification. However,
this reflects the actual clinical situation in most settings
treating acute poisoning, as well as current best practice
in toxicology, in which patients are managed based on
their clinical presentation.
The proportion of presentations with psychosis is not
a measure of a drug’s potential to induce psychosis. Ra-
ther, it is a measure of to what extent psychosis is part
of the problems associated with the drug’s acute toxicity.
For many drugs the numbers in our study are small, and
for these drugs the results should be interpreted with
caution.
Conclusions
There is considerable variation between drugs in how
commonly psychosis is a feature of acute recreational
drug toxicity. Psychosis was seen in a large proportion of
presentations with acute amphetamine toxicity. Amongst
the NPS, although numbers were small, psychosis was
rare in mephedrone and methedrone poisoning, but oc-
curred frequently with tryptamines, MDPV and the syn-
thetic cannabinoid receptor agonists; psychosis was also
common in presentations involving methylphenidate.
In rapidly changing drug markets, the Euro-DEN sen-
tinel network contributes to measuring the scale of
drug-related harms in Europe beyond other more estab-
lished European indicators [49–51]. Further study is re-
quired in larger cohorts to understand the associations
found and consider other factors such as the importance
of underlying psychiatric co-morbidity. However, in this
series, psychosis was seen in a significant minority of
presentations and this has important implications for
prevention, follow-up and referral for further treatment,
and represents an important burden on health services.
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